Veru to Announce Q2 Fiscal 2024 Results on May 8, 2024
MIAMI, FL, May 01, 2024 -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company in the late stages of clinical development, will hold a conference call and audio webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET. The purpose of the call is to discuss its financial results for the second quarter of fiscal 2024 and to provide an update on business activities.
The audio webcast can be accessed through the Investors page on the company's website. Those wishing to join the call by phone can dial 1-800-341-1602 (for domestic calls) or 1-412-902-6706 (for international calls) and request to join the Veru Inc. call. For those who cannot attend live, an archived version of the webcast will be available on the company's website for three months. A replay of the call will also be available from approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) with passcode 8861692, for one week.
Veru Inc. is dedicated to developing new medications for preserving muscle during high-quality weight loss, treating cancer, and addressing viral-induced acute respiratory distress syndrome (ARDS). The company's current drug development efforts include two advanced small molecules, enobosarm and sabizabulin.
Enobosarm, a selective androgen receptor modulator (SARM), is in development for two uses. The first is a Phase 2b clinical study aimed at reducing fat and preventing muscle loss in elderly obese or overweight patients at risk of muscle atrophy and weakness who are receiving a GLP-1 RA. The second use, contingent on adequate funding, is a Phase 3 clinical trial, ENABLAR-2, which combines enobosarm with abemaciclib to treat metastatic breast cancer in patients with AR+, ER+, and HER2- profiles as a second-line treatment.
Sabizabulin, known for its microtubule disrupting capabilities, is being explored in a Phase 3 clinical trial to treat hospitalized patients suffering from viral-induced ARDS. The continuation of sabizabulin's development for this indication is dependent on securing external funding sources such as government grants or partnerships with pharmaceutical companies.
Additionally, Veru Inc. markets an FDA-approved product, the FC2 Female Condom® (Internal Condom), designed for dual protection against unintended pregnancy and sexually transmitted infections.
This announcement allows stakeholders and potential investors to gain insight into Veru Inc.'s latest financial standings and future plans, particularly concerning their innovative drug developments and commercial products.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
